Butterfly Network nets new CEO ahead of going public

Butterfly Network iQ+
Public trading on the New York Stock Exchange is slated to begin Feb. 16 under the ticker "BFLY." (Butterfly Network)

Ahead of its upcoming merger and plans to go public, hand-held ultrasound developer Butterfly Network has named a new president and CEO. Todd Fruchterman, former president and general manager of 3M's $4.8 billion medical solutions division, will helm the company starting Feb. 1.

The announcement was made jointly with Butterfly’s corporate suitor, Longview Acquisition Corp., a special-purpose company backed by hedge fund Glenview Capital Management. Former CEO Laurent Faracci stepped down earlier this week.

The $1.5 billion acquisition deal was announced last November, following Longview’s $300 million IPO in early 2020.

Before spending nearly 10 years at 3M, where he also served as chief medical officer and chief technology officer, Fruchterman held roles at Acelity, Johnson & Johnson, Schering-Plough and Response Genetics. Since last fall, he has been group president of reliability solutions at contract manufacturer Flex.

"We are very excited Todd has joined Butterfly as President and CEO to lead the Company at this critical stage,” Butterfly founder and Chairman Jonathan Rothberg said. “Todd brings together his unique qualifications and experience as an M.D., Ph.D. and proven business executive in public medical device companies, where he has successfully scaled disruptive technologies throughout his entire career."

RELATED: Special Report—The top 10 M&A targets in medtech | Butterfly Network 

In addition, Butterfly and Longview have also put forward new names for the board of directors of the emerging public company. Joining Rothberg, Fruchterman and Glenview founder Larry Robbins, they include: Dawn Carfora, global business vice president at Facebook; John Hammergren, former McKesson chairman and CEO; Gianluca Pettiti, Thermo Fisher Scientific’s president of specialty diagnostics; and S. Louise Phanstiel, chair of the board at Myriad Genetics.

"I am grateful to these independent directors for supporting our movement to use Ultrasound-on-Chip technology to make safe diagnostic imaging more accessible, more affordable and more effective," Rothberg said. "We expect that their deep skills and directly relevant experiences will bring to the company wisdom and insight across operational, strategic, cultural and fiduciary spheres."

RELATED: Butterfly Network nets $250M to start shipping ultrasound-on-chip

Longview has scheduled a meeting Feb. 12 to approve its acquisition of Butterfly and elect the seven nominated directors, with the deal expected to close later that day. Public trading on the New York Stock Exchange is slated to begin Feb. 16 under the ticker "BFLY."